The application of the specific kinase inhibitor SD-208 to shield CD8+ and CD4+ ROR1-CAR T cells from the suppressive impact of TGF-β resulted in the consistent maintenance of their antitumor efficacy both in vitro and in the neurophysiologic 3D tumor model [29]. Here, CD8A is linked to neoplasm.